ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response

The mixture of ISA101, a human papilloma virus (HPV) 16 peptide vaccine, and nivolumab confirmed a promising response fee of 33% in sufferers with incurable HPV-16+ most cancers.